RestoreX Logo

is the world’s first polymer-based technology platform designed to enable cardiovascular restoration – through ETR


Endogenous Tissue Restoration (ETR) is a new therapeutic approach, enabling the patient’s own body to naturally restore a new blood vessel or heart valve.

With ETR, the patient’s natural healing system develops tissue that pervades Xeltis’ device, forming a new, natural and fully functional blood vessel or heart valve within it. As ETR occurs, Xeltis implants are gradually absorbed by the body.

ETR is enabled by bioabsorbable polymers based on Nobel Prize awarded science.

ETR In Action

Watch ETR video now

Xeltis devices work as normal heart valves or blood vessels once implanted.


New tissue forms around and inside the device to develop a new, healthy, functioning heart valve or blood vessel.


Xeltis devices are designed to absorb over time, leaving patients with a new, healthy, functioning heart valve or blood vessel.


RestoreX Logo

RestoreX™ is the world’s first polymer-based technology designed to enable natural restoration of cardiovascular function, through a therapeutic approach called Endogenous Tissue Restoration (ETR). ETR is enabled by bioabsorbable polymers based on Nobel Prize awarded science.

No in vitro tissue engineering

No stem cells

No biological agents

No animal tissue

20+ international patent families portfolio protecting Xeltis’ innovative supramolecular polymer platform and its electrospinning methodology for device manufacturing.

Electrospinning supramolecular polymers using electric force to draw supramolecular polymer solutions into threads that measure a fraction of the diameter of a hair.

Millions of patients with cardiovascular conditions requiring blood vessel or heart valve replacements potentially addressed with RestoreX™ technology.

Product Pipeline



Pediatric conduit

Pulmonary Heart Valve

Aortic Heart Valve

Cardiovascular Applications

Nobel Prize-Awarded Science

Professor Jean-Marie LehnJean-Marie Lehn, Nobel Laureate.
Awarded 1987 Nobel Prize in Chemistry for pioneering supramolecular chemistry, the science at the basis of Xeltis’ technology.

“Supramolecular chemistry enables Xeltis technology by providing unique biochemical and biomechanical properties, delivering solutions to issues faced by traditional materials over the course of decades.”
Professor Lehn is a Scientific Advisor to Xeltis.

Presented Data




Scientific Literature

Academic Partnerships

Xeltis is actively involved in research collaborations with leading academic partners.

Scientific research projects enable Xeltis to increase our knowledge of ETR, by leveraging the deep scientific understanding achieved at an academic level, and to contribute to our robust knowledge of technology application in the field.

The RegMed XB Institute brings together multiple health foundations, leading scientists, entrepreneurs and government institutions to cooperatively tackle ambitious challenges in regenerative medicine.

The ImaValve Consortium, led by Professor Bouten from Eindhoven University of Technology (TU/e), aims at using intelligent materials to develop innovative solutions for the challenging research field of in situcardiovascular restoration. The ImaValve is made of a slowly degrading elastomeric polymer that can be inserted with minimally invasive surgery.

The iValve-II project is a continuation from the BMM iValve project, with a public-private consortium led by Professor Bouten from TU/e. The focus of this academic collaboration is on using restorative approaches to repair or replace damaged tissues and organs.

The InSiTeVx Consortium, led by Professor Dankers from TU/e, is investigating whether the understanding on cardiovascular restoration from previous projects can be translated to develop an off-the-shelf, synthetic, biodegradable vascular access graft for dialysis.

RestoreX™ technology platform comprises investigational devices that are not available for sale.